📌 Key Takeaways
- On June 7, 2026, ScienceDaily reported that Polygonum multiflorum (He Shou Wu) — a plant used in Traditional Chinese Medicine for over 1,200 years —
may offer new pathways for treating androgenetic alopecia (AGA). - A December 2025 paper in the Journal of Holistic Integrative Pharmacy identified four distinct mechanisms:
DHT inhibition, Wnt signaling activation, antioxidant follicle protection, and scalp blood flow improvement. - However, hepatotoxicity (liver damage) has been documented in multiple case reports.
The European Medicines Agency (EMA) and other regulators have issued warnings.
Self-administration is not recommended at this stage.
For people who cannot tolerate minoxidil — or women excluded from finasteride use —
the search for alternative AGA treatments remains frustratingly limited.
On June 7, 2026, ScienceDaily published a report drawing attention to a plant
that has been used in Chinese traditional medicine for more than 1,200 years:
Polygonum multiflorum, known in Chinese medicine as He Shou Wu.
What makes this noteworthy is not the plant’s ancient history,
but the degree to which its mechanisms align with modern AGA pharmacology.
INDEX
What Is Polygonum Multiflorum (He Shou Wu)?
Scientific name: Polygonum multiflorum (also classified as Pleuropterus multiflorus).
A member of the Polygonaceae family, its root contains the primary bioactive compounds.
In Traditional Chinese Medicine (TCM), it has been used for over 1,200 years
to “tonify the kidneys, nourish the blood, and restore hair color.”
It appears in some supplements and topical hair products globally,
but its scientific classification as a validated therapeutic agent remains under investigation.
Four Mechanisms Identified by Modern Research
A December 2025 paper published in the Journal of Holistic Integrative Pharmacy
(Han B, Xiao M, Xin T et al.) systematically reviewed the AGA-related mechanisms
of Polygonum multiflorum.
The researchers noted a “remarkable convergence” between ancient TCM descriptions
and contemporary scientific findings.
The Critical Caveat: Hepatotoxicity Risk
⚠️ Hepatotoxicity Risk — The Most Significant Safety Concern
Hepatotoxicity (liver damage) associated with Polygonum multiflorum
has been documented in multiple case reports and peer-reviewed studies.
Risk levels vary significantly depending on preparation method, dosage,
and individual metabolic capacity (including genetic polymorphisms).
The European Medicines Agency (EMA) and regulatory bodies in multiple countries
have issued formal safety warnings regarding this plant.
In short: acting on “this might work” information alone —
without medical supervision — carries a real risk of serious liver injury.
Safety has not been sufficiently established for unsupervised use as a supplement or medicine.
The framing of “ancient herbal wisdom validated by modern science” is compelling —
and not entirely wrong.
But what NERO wants to emphasize is the word “preliminary.”
Two facts matter right now:
First, the AGA-related mechanisms of Polygonum multiflorum are scientifically interesting.
Second, hepatotoxicity risk makes self-administration genuinely dangerous.
Holding both of these truths simultaneously —
without collapsing into either dismissal or enthusiasm —
is the only intellectually honest position.
“Used for centuries”
and
“proven safe”
are not the same sentence.
Summary
- A December 2025 paper in the Journal of Holistic Integrative Pharmacy
identified four AGA-related mechanisms in Polygonum multiflorum (He Shou Wu):
DHT inhibition, Wnt signaling activation, antioxidant follicle protection,
and scalp blood flow improvement. - These mechanisms are directionally aligned with current first-line AGA treatments
(finasteride and minoxidil), making the research scientifically significant. - Hepatotoxicity risk is documented and formally flagged by the EMA and other regulators.
Self-administration is not recommended. - The correct stance is to hold both realities simultaneously:
promising preliminary science, and an unresolved safety profile.
in any major regulatory jurisdiction (FDA, EMA, or equivalent).
It remains in the research phase, with promising mechanistic data
but no large-scale clinical trials establishing efficacy or safety for this indication.
The European Medicines Agency (EMA) has issued formal warnings.
Risk varies by preparation method, dose, and individual genetic metabolism —
making it difficult to predict who is at risk without medical evaluation.
represent an underserved population in AGA treatment.
Polygonum multiflorum research is relevant to this group —
but the appropriate response is to monitor clinical trial developments,
not to self-administer supplements based on current evidence.
Sources:
Han B, Xiao M, Xin T et al. “Research progress on the application of Pleuropterus multiflorus in the treatment of androgenetic alopecia.” Journal of Holistic Integrative Pharmacy 2025;6(4):443. DOI: 10.1016/j.jhip.2025.12.005
ScienceDaily. “Ancient Chinese medicine could transform hair loss treatment.” June 7, 2026.
Dr Cinik. “New hair loss drugs in 2026: PP405, clascoterone, ET-02.” March 6, 2026.
Healthline. “Hair Loss: These Are the Best Treatments, Medications In 2026.” February 13, 2026.
